TBP.TO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 kov. 2023 @ 22:59):

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology...

Stats
Dzisiejszy wolumen	476 110
Średni wolumen	0.00
Kapitalizacja rynkowa	10.58M
EPS	$0 ( 2023-11-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.313
ATR14	$0 (0.00%)

Wolumen Korelacja

Długi: 0.06 (neutral)

Krótki: 0.00 (neutral)

Signal:(52.174) Neutral

TETRA BIO PHARMA INC Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TETRA BIO PHARMA INC Korelacja - Waluta/Towar

0.00
( neutral )

-0.14
( neutral )

TETRA BIO PHARMA INC Finanse

Annual	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.202

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.202

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.100

FY	2019
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0800

Financial Reports:

No articles found.

TETRA BIO PHARMA INC

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.